Sun Pharmaceutical Industries Ltd. / DUSA Pharmaceuticals, Inc.

Actinic Keratosis (face/scalp)

Disease Overview

Actinic keratoses are rough, scaly precancerous skin lesions caused by chronic UV exposure, most common on sun-exposed face, scalp, and arms in adults over 40. A subset progress to squamous cell carcinoma if untreated, making AK both a common dermatology visit driver and a skin cancer prevention opportunity.

Competitive Landscape

The 2012 US AK treatment market was fragmented across cryotherapy (provider-administered liquid nitrogen, the dominant first-line approach), topical agents (5-fluorouracil/Efudex/Carac, imiquimod/Aldara, diclofenac/Solaraze, and the newly-approved Picato/ingenol mebutate from LEO Pharma, FDA-approved January 2012), and photodynamic therapy. DUSA's Levulan Kerastick + BLU-U was the differentiated PDT play — an in-office two-step procedure where aminolevulinic acid is applied topically, then activated by blue light, generating reactive oxygen species that destroy AK lesions. PDT competed against Galderma's Metvixia (methyl aminolevulinate) but held the dominant US PDT share. For Sun Pharma, the deal was strategically asymmetric: $230M buys an FDA-approved branded dermatology platform with a captive razor/razor-blade device model, US sales infrastructure, and proven manufacturing — Sun's first US branded specialty entry. Analyst takes were broadly positive given the 38% premium was modest, DUSA's H1 2012 revenue was ~$37M and growing 20%+, and Sun gained immediate dermatology beachhead complementing its generics base. The acquisition closed December 2012 via tender offer. (Source: https://www.fiercepharma.com/pharma/sun-pharma-to-acquire-dusa-pharmaceuticals-inc)